GI Oncology Now Conference Coverage
GI Oncology Now reviews education from ASCO GI 2024, featuring the latest advances in the field of GI cancer research.
Coverage of the 2024 ASCO GI Symposium, focusing on liver cancer
GI Oncology Now reviews education from ISGIO 2023, featuring the latest advances in the field of GI cancer research.
GI Oncology Now reviews practice-enhancing education from CIO 2023, featuring multidisciplinary specialties in oncology.
Advertisement
The Latest From GI Oncology Now
Dr. Kimmie Ng shares the experiences that drive her dedication to seeking improved patient outcomes in GI oncology care.
A recent study compared first-line chemotherapy, as the standard of care for PDAC, with other treatment options.
A recent systematic review evaluated the relationship between NLR and the prognosis of patients who receive NAC.
Entinostat has been utilized in other solid tumors for its ability to induce the inhibition of cell proliferation.
Studies of asymptomatic and symptomatic patients have demonstrated lower ctDNA detection in asymptomatic patients.
In several different types of cancer, tumor budding is linked to poor survival outcomes.
The phase III study found that regorafenib improved overall survival in patients with refractory advanced gastric cancer.
Study participants were administered nadunolimab with a standard dose of gemcitabine and nab-paclitaxel (GN) every two weeks.
Advertisement
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.